You'll want this test so you can implement your doctor's EXACT DEMENTIA PREVENTION PROTOCOLS. Oh your doctor doesn't have one, well then you have an incompetent doctor who doesn't know about the Bredesen Protocol or anything else?
Bredesen Protocol(8 posts to September 2017)
Alzheimers prevention (120 posts to June 2012)
dementia prevention (176 posts to June 2015)
Your risk of dementia, has your doctor told you of this?
1. A documented 33% dementia chance post-stroke from an Australian study? May 2012.
2. Then this study came out and seems to have a range from 17-66%. December 2013.`
3. A 20% chance in this research. July 2013.
4. Dementia Risk Doubled in Patients Following Stroke September 2018
The latest here:
Early Alzheimer's Test Gets FDA Nod
First in vitro diagnostic to detect amyloid in early disease setting
The first in vitro diagnostic tool to help detect early Alzheimer's disease was authorized by the FDA on Wednesday.
The assay measures the ratio of beta-amyloid 1-42 to beta-amyloid 1-40 in cerebrospinal fluid (CSF). The Lumipulse G ß-Amyloid Ratio (1-42/1-40) test is intended to be used in adults 55 and older presenting with cognitive impairment who are being evaluated for Alzheimer's disease or other causes of cognitive decline.
Test results are consistent with amyloid PET scan results, the agency noted.
"The availability of an in vitro diagnostic test that can potentially eliminate the need for time-consuming and expensive PET scans is great news for individuals and families concerned with the possibility of an Alzheimer's disease diagnosis," said Jeff Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, in a statement.
"With the Lumipulse test, there is a new option that can typically be completed the same day and can give doctors the same information regarding brain amyloid status, without the radiation risk, to help determine if a patient's cognitive impairment is due to Alzheimer's disease," Shuren added.
The FDA evaluated the safety and effectiveness of the Lumipulse test in a clinical study of 292 CSF samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, which were compared with amyloid PET scan results.
Overall, 97% of ADNI participants with positive Lumipulse results had the presence of amyloid plaques on PET, and 84% of individuals with negative Lumipulse results had a negative amyloid scan, the agency said.
Risks associated with the test include the possibility of false positive or false negative results. "Importantly, the Lumipulse G β-amyloid Ratio (1-42/1-40) is not a stand-alone test and other clinical evaluations or additional tests should be used for determining treatment options," the FDA pointed out.
There's an unmet need for a reliable, safe test to identify patients with amyloid plaques consistent with Alzheimer's disease, the agency added. Amyloid plaques can occur in other diseases but being able to detect their presence, along with other evaluations, can help clinicians determine the probable cause of a patient's symptoms.
Much research in recent years has focused on blood as a new matrix for Alzheimer's biomarkers that already have been validated in CSF. A blood test for amyloid-beta has been widely available in the U.S. since 2020 under a CMS certification process for laboratories that tests patient samples, but is not yet FDA-approved.
FDA permitted marketing of the Lumipulse G ß-Amyloid Ratio (1-42/1-40) test to Fujirebio Diagnostics. The agency reviewed the assay through its de novo premarket review pathway. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.
No comments:
Post a Comment